Paul Baas, MD, PhD, of the Netherlands Cancer Institute, discusses the promise of immuno-oncology in the treatment of patients with mesothelioma. In second line, nivolumab and pembrolizumab are not as active; however, it may be more promising to combine these drugs. A press release indicated that combination treatment was successful in the first-line setting. Dr. Baas notes that chemotherapy plus durvalumab resulted in a positive 20-month median overall survival, which is longer than the normal 15 to 16 months seen previously.